Celltrion, Inc. (KRX:068270)

Market Cap	41.03T +6.2%
Revenue (ttm)	4.90T +30.6%
Net Income	1.58T +220.3%
EPS	6,840.22 +226.4%
Shares Out	228.43M
PE Ratio	26.26
Forward PE	28.95
Dividend	714.29 (0.40%)
Ex-Dividend Date	Dec 29, 2025

Volume	461,849
Open	182,000
Previous Close	183,500
Day's Range	179,500 - 182,300
52-Week Range	158,500 - 239,048
Beta	0.28
Analysts	Buy
Price Target	267,741.48 (+49.08%)
Est. Earnings	Nov 13, 2026

About Celltrion

Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and u...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2,956
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 068270

Financial Performance

In 2025, Celltrion's revenue was 4.16 trillion, an increase of 17.01% compared to the previous year's 3.56 trillion. Earnings were 1.03 trillion, an increase of 143.58%.

Analyst Summary

According to 22 analysts, the average rating for 068270 stock is "Buy." The 12-month stock price target is ₩267,741, which is an increase of 49.08% from the latest price.

Price Target

₩267,741

(49.08% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 9, 2026

Data Sources Report a data error